Ken Griffin Repligen Corp Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Repligen Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 57,000 shares of RGEN stock, worth $7.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,000

Previous 103,800 45.09%

Holding current value

$7.92 Million

Previous $13.1 Million 35.18%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$119.79 - $167.35 $61.4 Million - $85.8 Million	512,438 Added 14970.44%	515,861 $76.8 Million
Q2 2024 Aug 14, 2024	SELL	$120.0 - $182.95 $12.2 Million - $18.6 Million	-101,822 Reduced 96.75%	3,423 $431,000
Q1 2024 May 15, 2024	SELL	$170.78 - $208.42 $29.9 Million - $36.5 Million	-175,233 Reduced 62.48%	105,245 $19.4 Million
Q4 2023 Feb 14, 2024	SELL	$114.17 - $185.35 $13.4 Million - $21.7 Million	-117,069 Reduced 29.45%	280,478 $50.4 Million
Q3 2023 Nov 14, 2023	BUY	$138.78 - $176.51 $43.3 Million - $55.1 Million	312,109 Added 365.3%	397,547 $63.2 Million
Q2 2023 Aug 14, 2023	BUY	$138.42 - $180.31 $11.1 Million - $14.4 Million	80,048 Added 1485.12%	85,438 $12.1 Million
Q1 2023 May 15, 2023	BUY	$154.26 - $198.1 $791,970 - $1.02 Million	5,134 Added 2005.47%	5,390 $907,000
Q4 2022 Feb 14, 2023	SELL	$162.42 - $220.56 $4.33 Million - $5.88 Million	-26,637 Reduced 99.05%	256 $43,000
Q3 2022 Nov 14, 2022	SELL	$160.42 - $256.21 $8.94 Million - $14.3 Million	-55,716 Reduced 67.45%	26,893 $5.03 Million
Q2 2022 Aug 15, 2022	BUY	$140.68 - $188.02 $7.68 Million - $10.3 Million	54,625 Added 195.2%	82,609 $13.4 Million
Q1 2022 May 16, 2022	SELL	$161.19 - $257.96 $12.9 Million - $20.7 Million	-80,248 Reduced 74.14%	27,984 $5.26 Million
Q4 2021 Feb 14, 2022	BUY	$247.59 - $304.47 $20.3 Million - $25 Million	82,175 Added 315.37%	108,232 $28.7 Million
Q3 2021 Nov 15, 2021	SELL	$194.77 - $324.21 $54.2 Million - $90.2 Million	-278,258 Reduced 91.44%	26,057 $7.53 Million
Q2 2021 Aug 16, 2021	BUY	$165.87 - $220.95 $49.5 Million - $65.9 Million	298,126 Added 4817.03%	304,315 $60.7 Million
Q1 2021 May 17, 2021	SELL	$180.37 - $226.26 $8.53 Million - $10.7 Million	-47,275 Reduced 88.42%	6,189 $1.2 Million
Q4 2020 Feb 16, 2021	SELL	$148.08 - $206.57 $16.1 Million - $22.5 Million	-108,944 Reduced 67.08%	53,464 $10.2 Million
Q3 2020 Nov 16, 2020	BUY	$122.51 - $158.27 $1.62 Million - $2.1 Million	13,251 Added 8.88%	162,408 $24 Million
Q2 2020 Aug 14, 2020	BUY	$94.33 - $140.48 $11.5 Million - $17.1 Million	121,524 Added 439.78%	149,157 $18.4 Million
Q1 2020 May 15, 2020	SELL	$84.96 - $109.14 $5.9 Million - $7.58 Million	-69,458 Reduced 71.54%	27,633 $2.67 Million
Q4 2019 Feb 14, 2020	SELL	$73.84 - $93.08 $4.55 Million - $5.74 Million	-61,636 Reduced 38.83%	97,091 $8.98 Million
Q3 2019 Nov 14, 2019	BUY	$76.65 - $95.51 $9.07 Million - $11.3 Million	118,330 Added 292.92%	158,727 $12.2 Million
Q2 2019 Aug 14, 2019	SELL	$54.2 - $85.95 $4.4 Million - $6.99 Million	-81,273 Reduced 66.8%	40,397 $3.47 Million
Q1 2019 May 15, 2019	SELL	$49.45 - $62.8 $7.85 Million - $9.97 Million	-158,793 Reduced 56.62%	121,670 $0
Q4 2018 Feb 14, 2019	BUY	$48.26 - $68.88 $12.1 Million - $17.3 Million	251,283 Added 861.15%	280,463 $14.8 Million
Q3 2018 Nov 13, 2018	BUY	$46.8 - $58.97 $989,164 - $1.25 Million	21,136 Added 262.75%	29,180 $0
Q2 2018 Aug 10, 2018	BUY	$35.26 - $47.04 $283,631 - $378,389	8,044 New	8,044 $0
Q1 2018 May 11, 2018	SELL	$30.92 - $37.27 $561,723 - $677,084	-18,167 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$32.53 - $38.92 $590,972 - $707,059	18,167	18,167 $659,000

Others Institutions Holding RGEN

# of Institutions

486

Shares Held

54.3M

Call Options Held

341K

Put Options Held

235K

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $7.71B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account